Parallax Volatility Advisers
MCRB icon

Parallax Volatility Advisers’s Seres Therapeutics MCRB Stock Holding History

Parallax Volatility Advisers’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,800
Closed -$50.4K – 2145
2023
Q4 		$50.4K Hold
1,800
– – ﹤0.01% 1931
2023
Q3 		$85.7K Buy
+1,800
New +$137K ﹤0.01% 1956

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Parallax Volatility Advisers's MCRB Position: Q1 2024 in Review

Parallax Volatility Advisers sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 2,158 shares — an estimated $60.4K sold.

Parallax Volatility Advisers first reported a position in MCRB in Q4 2017 and held it in 6 quarters. The position peaked at $646K in Q2 2023. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

  • Parallax Volatility Advisers reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,158 Seres Therapeutics shares in Q1 2024, an estimated $60.4K.
  • Parallax Volatility Advisers first reported a position in Seres Therapeutics in Q4 2017 and held it in 6 quarters.
  • Parallax Volatility Advisers's Seres Therapeutics position peaked at $646K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Parallax Volatility Advisers's 13F filing for Q1 2024, filed 15 May 2024.